宣白承氣湯聯(lián)合西醫(yī)常規(guī)治療慢性阻塞性肺疾病急性加重期系統(tǒng)評(píng)價(jià)

性加重期系統(tǒng)評(píng)價(jià)Abstract：ObjectiveToreviewtheefficacyandsafetyofXuanbaiChengqi Decoction combined with western medicine for thetreatmentofexacerbationofchronicobstructivepulmonarydisease（AECOPD）systematically.MethodsRandomizedcontrolledtrialsofmodified Xuanbai Chengqi Decoction combined with WesternmedicineroutinetreatmentandWesternmedicineinthetreatmentofAECOPDwereretrievedfromCNKI，VIP，WanfangDataandPubmeddatabases.TheCochraneHandbookforSystematicReviewswasusedforliteraturequalityevaluationanddataextraction，andRevMan5.3wasusedformeta-analysisonclinicalefficacyindicators.ResultsTotallytwelvearticleswereincluded.Thetotaleffectiverateofthetreatmentgroupwashigherthanthatinthecontrolwithle，%I（，，0Comparedwiththecontrolthetreatmentgroupsignificantlyreducedthepercentageofneutrophils，inflammatorymarkerssuchasC-reactiveproteinandarterialbloodcarbondioxidepartialpressure，andsignificantlyincreasedthepercentageofforcedyenetd1，dl（FVC）asapercentageofpredictedvalue，F(xiàn)EV1/FVC，arterialbloodpHandarterialoxygenpartialwithstatisticalsignificance.Noseriousadversereactionswerereportedintheliterature.ConclusionModifiedXuanbaiChengqiDecoctioncombinedwithwesternmedicineinthetreatmentofAECOPDhassignificantefficacy.However，duetothesmallamountofliteratureandsmallsamplethequalityofthestudyisanditsclinicalefficacydyleyrandomizedtrialstofurtherverify.

large-sample，andKeywords：XuanbaiChengqiDecoction;acuteexacerbationofchronicobstructivepulmonarydisease;randomizedcontrolledtrials;Meta-analysis慢性阻塞性肺疾?。╟hronicobstructivepulmonarydisease，COPD）是全球無(wú)法治愈的主要健康負(fù)擔(dān)。慢性阻塞性肺疾病急性加AECOPD的常規(guī)治療以止咳抗感染、化痰止痙、低濃度氧療等為主。宣白承氣AECOPD患者多以咳嗽、氣短或喘息加重、痰量增多呈膿性或黏液膿性、發(fā)熱為主，同時(shí)伴有便秘，與AECOPD的隨機(jī)對(duì)照試驗(yàn)Meta分析，AECOPD提供循證醫(yī)學(xué)證據(jù)。資料與方法數(shù)據(jù)來(lái)源中文文獻(xiàn)檢索數(shù)據(jù)庫(kù)包括中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)（、中（（萬(wàn)方數(shù)據(jù)（慢阻肺R慢性阻塞性肺病ORCOPDOROR慢性阻塞性肺OROR宣白承氣OROROR試驗(yàn)PubmedobstructivepulmonarydiseaseORExacerba